Sugi Predict

Sugi Predict / Compounds / Pazoxide

Pazoxide

Pazoxide

SCHEMBL122399

O=S1(=O)N=C(C2CC=CC2)Nc2cc(Cl)c(Cl)cc21

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 5/20 0.39
▸ CYP3A4 P08684 3/20 0.39
▸ TSHR P16473 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ ABCC8 Q09428 1/20 0.39
▸ KCNJ11 Q14654 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ NR1I2 O75469 1/20 0.32
▸ ABCB11 O95342 1/20 0.32
▸ ADRA2A P08913 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ ADRA2B P18089 1/20 0.32
▸ ADRA2C P18825 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719059 0.88 CYP3A4 (0.41) CYP2D6CYP3A4TSHRALDH1A1SMN1; SMN2
SCHEMBL720876 0.84 ABCC8 (0.44) CYP2D6CYP3A4TSHRALDH1A1SMN1; SMN2
SCHEMBL718987 0.71 CYP3A4 (0.71) CYP2D6CYP3A4TSHRALDH1A1SMN1; SMN2
SCHEMBL719274 0.70 CYP3A4 (0.38) CYP2D6CYP3A4TSHRALDH1A1SMN1; SMN2
SCHEMBL6553558 0.68 ABCC8 (0.37) CYP2D6CYP3A4TSHRALDH1A1SMN1; SMN2
SCHEMBL717822 0.68 CYP3A4 (0.42) CYP2D6CYP3A4TSHRALDH1A1SMN1; SMN2
Pazoxide SCHEMBL28279749 0.67 CYP2D6 (0.30) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL7951060 0.66 THRB (0.40) CYP2D6CYP3A4TSHRALDH1A1SMN1; SMN2
SCHEMBL4708802 0.64 KMT2A (0.43) CYP2D6CYP3A4TSHRALDH1A1SMN1; SMN2
SCHEMBL719962 0.63 CYP3A4 (0.67) CYP2D6CYP3A4TSHRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 — — US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 — — US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
US-20020115655-A1 Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders MASSACHUSETTS COLLEGE OF PHARMACY 2002-08-22 — — US claimed
EP-4706683-A2 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2026-03-11 — — EP disclosed
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES AQUESTIVE THERAPEUTICS, INC. (US) 2026-02-05 — — US disclosed
US-12465564-B2 Oral and nasal compositions and methods of treatment AQUESTIVE THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-20250339367-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES AQUESTIVE THERAPEUTICS, INC. (US) 2025-11-06 — — US disclosed
WO-2000050020-A2 USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS UNIVERSITY OF CINCINNATI (US) 2000-08-31 — — WO disclosed
WO-1999030690-A1 ORAL DELIVERY FORMULATION AXIA THERAPEUTICS, INC. (US) 1999-06-24 — — WO disclosed
EP-0909183-A2 DHA-PHARMACEUTICAL AGENT CONJUGATES Neuromedica, Inc. (US) 1999-04-21 — — EP disclosed
US-5795909-A ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS NEUROMEDICA, INC. (US) 1998-08-18 — — US disclosed
WO-1997044063-A2 DHA-PHARMACEUTICAL AGENT CONJUGATES NEUROMEDICA, INC. (US) 1997-11-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES SORD, SLC6A13, CACNA1A CYP2D6 216/4885CYP3A4 143/4885TSHR 2501/4885
US-20020115655-A1 Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders CACNA1G, CACNA1F, CACNA1H CYP2D6 991/4885CYP3A4 1171/4885TSHR 4456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.